SG10201500821UA - Common light chain mouse - Google Patents
Common light chain mouseInfo
- Publication number
- SG10201500821UA SG10201500821UA SG10201500821UA SG10201500821UA SG10201500821UA SG 10201500821U A SG10201500821U A SG 10201500821UA SG 10201500821U A SG10201500821U A SG 10201500821UA SG 10201500821U A SG10201500821U A SG 10201500821UA SG 10201500821U A SG10201500821U A SG 10201500821UA
- Authority
- SG
- Singapore
- Prior art keywords
- light chain
- common light
- chain mouse
- mouse
- common
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/20—Pseudochromosomes, minichrosomosomes
- C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Veterinary Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Environmental Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Toxicology (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Mycology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30228210P | 2010-02-08 | 2010-02-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201500821UA true SG10201500821UA (en) | 2015-04-29 |
Family
ID=43663643
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG2012057485A SG183149A1 (en) | 2010-02-08 | 2011-02-08 | Common light chain mouse |
SG10201500821UA SG10201500821UA (en) | 2010-02-08 | 2011-02-08 | Common light chain mouse |
SG10201913463QA SG10201913463QA (en) | 2010-02-08 | 2011-02-08 | Common light chain mouse |
SG10201610294RA SG10201610294RA (en) | 2010-02-08 | 2013-03-05 | Common light chain mouse |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG2012057485A SG183149A1 (en) | 2010-02-08 | 2011-02-08 | Common light chain mouse |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201913463QA SG10201913463QA (en) | 2010-02-08 | 2011-02-08 | Common light chain mouse |
SG10201610294RA SG10201610294RA (en) | 2010-02-08 | 2013-03-05 | Common light chain mouse |
Country Status (30)
Country | Link |
---|---|
US (5) | US10143186B2 (fr) |
EP (4) | EP3540066A1 (fr) |
JP (8) | JP5955781B2 (fr) |
KR (5) | KR101829691B1 (fr) |
CN (2) | CN105010238B (fr) |
AU (1) | AU2011213585B2 (fr) |
BR (2) | BR122014002928A2 (fr) |
CA (1) | CA2789154C (fr) |
CY (2) | CY1118241T1 (fr) |
DK (3) | DK3095871T3 (fr) |
ES (3) | ES2728942T3 (fr) |
HK (2) | HK1231505A1 (fr) |
HR (3) | HRP20151188T4 (fr) |
HU (3) | HUE026229T2 (fr) |
IL (3) | IL221265B (fr) |
LT (2) | LT3095871T (fr) |
ME (2) | ME02646B (fr) |
MX (3) | MX350983B (fr) |
MY (1) | MY166529A (fr) |
NZ (4) | NZ631363A (fr) |
PL (3) | PL2505654T5 (fr) |
PT (3) | PT2505654T (fr) |
RS (3) | RS55315B2 (fr) |
RU (2) | RU2724663C2 (fr) |
SG (4) | SG183149A1 (fr) |
SI (3) | SI3095871T1 (fr) |
SM (2) | SMT201500283B (fr) |
TR (1) | TR201906650T4 (fr) |
WO (1) | WO2011097603A1 (fr) |
ZA (1) | ZA201205944B (fr) |
Families Citing this family (197)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US20050144655A1 (en) | 2000-10-31 | 2005-06-30 | Economides Aris N. | Methods of modifying eukaryotic cells |
ES2368733T3 (es) | 2002-07-18 | 2011-11-21 | Merus B.V. | Producción recombinante de mezclas de anticuerpos. |
USRE47770E1 (en) | 2002-07-18 | 2019-12-17 | Merus N.V. | Recombinant production of mixtures of antibodies |
EP2395016A3 (fr) | 2003-05-30 | 2012-12-19 | Merus B.V. | Conception et utilisation de régions variables appariées de molécules de liaison spécifiques |
US20100069614A1 (en) | 2008-06-27 | 2010-03-18 | Merus B.V. | Antibody producing non-human mammals |
CN101506235B (zh) | 2006-09-01 | 2012-07-25 | 人类多细胞株治疗学公司 | 人或人源化免疫球蛋白在非人转基因动物中增强的表达 |
EP3456193A1 (fr) * | 2008-06-27 | 2019-03-20 | Merus N.V. | Mammifères non humains produisant un anticorps |
WO2010070263A1 (fr) | 2008-12-18 | 2010-06-24 | Erasmus University Medical Center Rotterdam | Animaux transgeniques non humains exprimant des anticorps humanises et leur utilisation |
US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
US9445581B2 (en) | 2012-03-28 | 2016-09-20 | Kymab Limited | Animal models and therapeutic molecules |
ES2537239T3 (es) | 2009-07-08 | 2015-06-03 | Kymab Limited | Modelos de animales y moléculas terapéuticas |
BR122014002928A2 (pt) * | 2010-02-08 | 2015-12-29 | Regeneron Pharma | métodos de produzir um camundongo e um anticorpo e de selecionar uma região variável de cadeia pesada humana para a produção de uma proteína de ligação ao antígeno, uso de um camundongo geneticamente modificado na produção de uma proteína de ligação ao antígeno, bem como anticorpo quimérico e hibridoma |
US20120021409A1 (en) * | 2010-02-08 | 2012-01-26 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
US9796788B2 (en) | 2010-02-08 | 2017-10-24 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
US20130045492A1 (en) | 2010-02-08 | 2013-02-21 | Regeneron Pharmaceuticals, Inc. | Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain |
BR122020013427B1 (pt) * | 2010-06-22 | 2021-08-03 | Regeneron Pharmaceuticals, Inc | Método para fazer um camundongo, uma célula ou tecido derivado de um camundongo e um hibridoma |
MX363084B (es) | 2010-08-02 | 2019-03-07 | Regeneron Pharma | Ratones que producen proteinas de union que comprenden dominios vl. |
WO2012071592A2 (fr) * | 2010-11-27 | 2012-05-31 | James Zhu | Animal transgénique humanisé |
CN103429746B (zh) | 2011-02-25 | 2016-05-11 | 瑞泽恩制药公司 | Adam6小鼠 |
CA2825081A1 (fr) | 2011-02-28 | 2012-09-07 | Birgit Bossenmaier | Proteines de liaison a un antigene |
WO2012116927A1 (fr) | 2011-02-28 | 2012-09-07 | F. Hoffmann-La Roche Ag | Protéines monovalentes de liaison à l'antigène |
SG2014007686A (en) * | 2011-08-05 | 2014-03-28 | Regeneron Pharma | Humanized universal light chain mice |
WO2013041845A2 (fr) * | 2011-09-19 | 2013-03-28 | Kymab Limited | Animaux, répertoires & procédés |
CN103945689B (zh) | 2011-09-19 | 2016-10-19 | 科马布有限公司 | 免疫球蛋白基因多样性的操纵及多抗体治疗剂 |
CA2791109C (fr) | 2011-09-26 | 2021-02-16 | Merus B.V. | Generation de molecules de liaison |
WO2013045916A1 (fr) | 2011-09-26 | 2013-04-04 | Kymab Limited | Chaînes légères substituts (cls) chimères comprenant vpreb humain |
GB2495083A (en) * | 2011-09-26 | 2013-04-03 | Kymab Ltd | Human VpreB and chimaeric surrogate light chains in transgenic non-human vertebrates |
BR112014007487A2 (pt) * | 2011-09-30 | 2017-04-04 | Dana Farber Cancer Inst Inc | peptídeos terapêuticos |
EP4074833A1 (fr) | 2011-10-17 | 2022-10-19 | Regeneron Pharmaceuticals, Inc. | Souris à chaîne lourde d'immunoglobuline limitée |
WO2013063391A2 (fr) | 2011-10-28 | 2013-05-02 | Trianni, Inc. | Animaux transgéniques et leurs procédés d'utilisation |
US9253965B2 (en) | 2012-03-28 | 2016-02-09 | Kymab Limited | Animal models and therapeutic molecules |
RU2664181C2 (ru) | 2011-12-20 | 2018-08-15 | Регенерон Фармасьютикалз, Инк. | Мыши с гуманизированной легкой цепью |
SG10201610123UA (en) | 2012-03-02 | 2017-01-27 | Regeneron Pharma | Human antibodies to clostridium difficile toxins |
SG11201405088QA (en) * | 2012-03-06 | 2014-11-27 | Regeneron Pharma | Common light chain mouse |
AU2015227453B2 (en) * | 2012-03-16 | 2017-05-25 | Regeneron Pharmaceuticals, Inc. | Non-human animals expressing ph-sensitive immunoglobulin sequences |
HUE045537T2 (hu) * | 2012-03-16 | 2019-12-30 | Regeneron Pharma | PH-érzékeny immunglobulin-szekvenciákat expresszáló rágcsálók |
US20140013456A1 (en) | 2012-03-16 | 2014-01-09 | Regeneron Pharmaceuticals, Inc. | Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same |
LT2883449T (lt) | 2012-03-16 | 2018-05-10 | Regeneron Pharmaceuticals, Inc. | Histidinu modifikuoti lengvosios grandinės antikūnai ir juos gaminantys genetiškai modifikuoti graužikai |
KR20140134672A (ko) * | 2012-03-16 | 2014-11-24 | 리제너론 파마슈티칼스 인코포레이티드 | pH-의존성 결합 특성을 나타내는 항원-결합 단백질을 생성하는 마우스 |
GB2502127A (en) | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
US10251377B2 (en) | 2012-03-28 | 2019-04-09 | Kymab Limited | Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies |
WO2013157953A1 (fr) | 2012-04-20 | 2013-10-24 | Merus B.V. | Procédés et moyens de production de molécules de type ig |
CA2872908C (fr) * | 2012-05-10 | 2023-11-14 | Gerhard Frey | Anticorps monoclonaux multi-specifiques |
JP2015525071A (ja) * | 2012-06-05 | 2015-09-03 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | 共通の軽鎖を用いて完全ヒト型二重特異性抗体を作製するための方法 |
NZ717848A (en) | 2012-06-12 | 2019-03-29 | Regeneron Pharma | Humanized non-human animals with restricted immunoglobulin heavy chain loci |
WO2014022540A1 (fr) | 2012-08-02 | 2014-02-06 | Regeneron Pharmaceuticals, Inc. | Protéines multivalentes de liaison à un antigène |
JO3462B1 (ar) | 2012-08-22 | 2020-07-05 | Regeneron Pharma | أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها |
JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
HUE042040T2 (hu) | 2012-09-27 | 2019-06-28 | Merus Nv | Bispecifikus IGG antitestek mint T-sejt kapcsolók |
SI2943511T1 (sl) | 2013-01-14 | 2020-01-31 | Xencor, Inc. | Novi heterodimerni proteini |
CA2900832A1 (fr) * | 2013-02-20 | 2014-08-28 | Regeneron Pharmaceuticals, Inc. | Souris exprimant des co-recepteurs de lymphocytes t humanises |
KR20160025033A (ko) | 2013-02-20 | 2016-03-07 | 리제너론 파마슈티칼스 인코포레이티드 | 변형된 면역글로불린 중쇄 서열을 갖는 비인간 동물 |
US10154658B2 (en) * | 2013-02-22 | 2018-12-18 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex mice |
CN108464278B (zh) * | 2013-03-11 | 2021-05-04 | 瑞泽恩制药公司 | 表达嵌合的主要组织相容性复合物(mhc)ii类分子的转基因小鼠 |
CN105189545A (zh) * | 2013-03-13 | 2015-12-23 | 瑞泽恩制药公司 | 常见轻链小鼠 |
BR112015022034B1 (pt) * | 2013-03-13 | 2023-02-28 | Regeneron Pharmaceuticals, Inc | Método de fabricar um camundongo, e, para fabricar um anticorpo |
EP3841876A1 (fr) | 2013-03-14 | 2021-06-30 | Erasmus University Medical Center Rotterdam | Souris transgénique destiné à la production d'anticorps |
US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
US9788534B2 (en) | 2013-03-18 | 2017-10-17 | Kymab Limited | Animal models and therapeutic molecules |
KR102049990B1 (ko) | 2013-03-28 | 2019-12-03 | 삼성전자주식회사 | c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질 |
SG10201800492PA (en) | 2013-04-29 | 2018-03-28 | Hoffmann La Roche | Human fcrn-binding modified antibodies and methods of use |
US9783618B2 (en) | 2013-05-01 | 2017-10-10 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
US20150033372A1 (en) * | 2013-05-01 | 2015-01-29 | Kymab Limited | Human VpreB & Chimaeric Surrogate Light Chains in Transgenic Non-Human Vertebrates |
US11707056B2 (en) | 2013-05-02 | 2023-07-25 | Kymab Limited | Animals, repertoires and methods |
US9783593B2 (en) | 2013-05-02 | 2017-10-10 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
CN111019953A (zh) | 2013-09-18 | 2020-04-17 | 瑞泽恩制药公司 | 组氨酸工程改造的轻链抗体和用于生成所述抗体的经基因修饰的非人动物 |
CA2922950A1 (fr) | 2013-09-30 | 2015-04-02 | Shinya Ishii | Procede de production d'une molecule de liaison a l'antigene dans lequel on utilise un phage auxiliaire modifie |
DE112014004537T5 (de) * | 2013-10-01 | 2016-07-21 | Kymab Limited | Tiermodelle und therapeutische Moleküle |
MX2016003593A (es) | 2013-10-11 | 2016-06-02 | Hoffmann La Roche | Anticuerpos de cadena ligera variable comun intercambiada de dominio multiespecifico. |
EP3094648A1 (fr) | 2014-01-15 | 2016-11-23 | F. Hoffmann-La Roche AG | Variants de région fc présentant une liaison améliorée à la protéine a |
RU2727639C2 (ru) | 2014-01-15 | 2020-07-22 | Ф.Хоффманн-Ля Рош Аг | Варианты fc-области с модифицированной способностью связываться с fcrn и с сохраненной способностью связываться с белком а |
TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗pd-l1之人類抗體 |
TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對pd-1的人類抗體 |
EP3470435B1 (fr) | 2014-02-28 | 2020-08-05 | Merus N.V. | Anticorps liant erbb-2 et erbb-3 |
US10844127B2 (en) | 2014-02-28 | 2020-11-24 | Merus N.V. | Antibodies that bind EGFR and ErbB3 |
TWI701042B (zh) | 2014-03-19 | 2020-08-11 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
AU2015230938C1 (en) | 2014-03-21 | 2021-10-14 | Regeneron Pharmaceuticals, Inc. | Non-human animals that make single domain binding proteins |
BR112016021679A2 (pt) | 2014-03-21 | 2018-12-04 | Regeneron Pharmaceuticals, Inc. | proteína de ligação ao antígeno, métodos de produção de uma proteína de ligação ao antígeno e de identificação de uma ou mais proteínas de ligação ao antígeno, hibridoma, ácido nucleico, célula, e, animal não humano geneticamente modificado. |
MY186389A (en) | 2014-05-13 | 2021-07-22 | Univ Pennsylvania | Compositions comprising aav expressing dual antibody constructs and uses thereof |
LT3151921T (lt) | 2014-06-06 | 2019-12-10 | Bristol Myers Squibb Co | Antikūnai prieš gliukokortikoidu indukuojamą naviko nekrozės faktoriaus receptorių (gitr) ir jų panaudojimas |
JP2017529841A (ja) | 2014-09-19 | 2017-10-12 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | キメラ抗原受容体 |
WO2016054598A2 (fr) | 2014-10-03 | 2016-04-07 | Massachusetts Institute Of Technology | Anticorps qui se lient à la glycoprotéine du virus ébola et utilisations associés |
MX2017005150A (es) | 2014-11-06 | 2017-08-08 | Hoffmann La Roche | Variantes de region fc con propiedades modificadas de union a receptor neonatal fc (fcrn) y proteina a. |
KR102614189B1 (ko) | 2014-11-17 | 2023-12-18 | 리제너론 파아마슈티컬스, 인크. | Cd3xcd20 이특이적 항체를 이용한 종양의 치료 방법 |
JP6805142B2 (ja) | 2014-11-21 | 2020-12-23 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Cd73に対する抗体およびその使用 |
US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
NZ732144A (en) | 2014-11-26 | 2020-04-24 | Xencor Inc | Heterodimeric antibodies that bind cd3 and tumor antigens |
WO2016097865A1 (fr) | 2014-12-19 | 2016-06-23 | Regenesance B.V. | Anticorps qui se lient au c6 humain et utilisations de ceux-ci |
TWI702229B (zh) | 2014-12-19 | 2020-08-21 | 美商再生元醫藥公司 | 流行性感冒病毒血球凝集素之人類抗體 |
CN107207594B (zh) | 2014-12-23 | 2019-05-07 | 百时美施贵宝公司 | 针对tigit的抗体 |
AU2016232715A1 (en) | 2015-03-19 | 2017-09-28 | Regeneron Pharmaceuticals, Inc. | Non-human animals that select for light chain variable regions that bind antigen |
KR20180010264A (ko) | 2015-05-29 | 2018-01-30 | 브리스톨-마이어스 스큅 컴퍼니 | Ox40에 대한 항체 및 그의 용도 |
EP3313886A1 (fr) | 2015-06-29 | 2018-05-02 | The Rockefeller University | Anticorps anti-cd40 présentant une activité agoniste renforcée |
SG10202112460VA (en) | 2015-07-06 | 2021-12-30 | Regeneron Pharma | Multispecific antigen-binding molecules and uses thereof |
EA201890028A1 (ru) | 2015-07-10 | 2018-08-31 | Мерус Н.В. | Антитело, связывающее cd3 человека |
JOP20160154B1 (ar) | 2015-07-31 | 2021-08-17 | Regeneron Pharma | أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها |
JP7023231B2 (ja) | 2015-09-23 | 2022-02-21 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 最適化抗cd3二重特異性抗体及びその使用 |
TWI756187B (zh) | 2015-10-09 | 2022-03-01 | 美商再生元醫藥公司 | 抗lag3抗體及其用途 |
KR20180100305A (ko) | 2015-10-23 | 2018-09-10 | 메뤼스 엔.페. | 암 성장을 억제하는 결합 분자 |
SG11201803817PA (en) | 2015-11-19 | 2018-06-28 | Bristol Myers Squibb Co | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof |
IL313952A (en) | 2015-12-22 | 2024-08-01 | Regeneron Pharma | Combination of anti-PD-1 antibodies and bispecific anti-CD20 / anti-CD3 antibodies for cancer treatment |
JP6979955B2 (ja) | 2016-01-13 | 2021-12-15 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | 操作された重鎖可変領域を有する齧歯類 |
JP2019514844A (ja) | 2016-03-04 | 2019-06-06 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | 抗cd73抗体を用いた併用療法 |
CN116063494A (zh) | 2016-03-04 | 2023-05-05 | 洛克菲勒大学 | 具有增强的激动剂活性的cd40的抗体 |
EP3448891A1 (fr) | 2016-04-28 | 2019-03-06 | Regeneron Pharmaceuticals, Inc. | Procédés de production de molécules multispécifiques se liant à l'antigène |
MX2018013072A (es) | 2016-05-09 | 2019-03-21 | Squibb Bristol Myers Co | Anticuerpos del ligando similar al factor de necrosis tumoral 1a (tl1a) y usos de los mismos. |
TWI786044B (zh) | 2016-05-13 | 2022-12-11 | 美商再生元醫藥公司 | 藉由投予pd-1抑制劑治療皮膚癌之方法 |
US20170332610A1 (en) | 2016-05-20 | 2017-11-23 | Regeneron Pharmaceuticals, Inc. | Methods for breaking immunological tolerance using multiple guide rnas |
SG11201810757YA (en) | 2016-06-03 | 2018-12-28 | Regeneron Pharma | Non-human animals expressing exogenous terminal deoxynucleotidyltransferase |
EP4374922A3 (fr) | 2016-06-14 | 2024-08-28 | Regeneron Pharmaceuticals, Inc. | Anticorps anti-c5 et leurs utilisations |
CA3029209A1 (fr) * | 2016-06-21 | 2017-12-28 | Teneobio, Inc. | Anticorps se liant a cd3 |
CN116063545A (zh) | 2016-06-28 | 2023-05-05 | Xencor股份有限公司 | 结合生长抑素受体2的异源二聚抗体 |
UY37325A (es) | 2016-07-14 | 2018-01-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Anticuerpos monoclonales que se enlazan a tim3 para estimular respuestas inmunitarias y composiciones que los contienen |
AU2017315146A1 (en) | 2016-08-26 | 2019-04-11 | Sanofi | Multispecific antibodies facilitating selective light chain pairing |
WO2018044970A1 (fr) | 2016-08-31 | 2018-03-08 | University Of Rochester | Anticorps monoclonaux humains dirigés contre l'enveloppe du rétrovirus endogène humain k (herv-k) et leurs utilisations |
CN109843325B (zh) * | 2016-09-14 | 2023-10-03 | 特尼奥生物股份有限公司 | Cd3结合抗体 |
AU2017331361B2 (en) | 2016-09-23 | 2024-07-18 | Regeneron Pharmaceuticals, Inc. | Anti-STEAP2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind STEAP2 and CD3, and uses thereof |
RS63660B1 (sr) | 2016-09-23 | 2022-11-30 | Regeneron Pharma | Anti-muc16 (mucin 16) antitela |
AU2017343778A1 (en) | 2016-10-13 | 2019-05-02 | Massachusetts Institute Of Technology | Antibodies that bind Zika virus envelope protein and uses thereof |
MA46814B2 (fr) | 2017-02-10 | 2022-09-30 | Regeneron Pharma | Anticorps anti-lag3 radiomarqués pour imagerie immuno-pet |
CN110506057B (zh) | 2017-02-17 | 2023-09-29 | 百时美施贵宝公司 | Alpha突触核蛋白抗体及其应用 |
EP3589650A1 (fr) | 2017-03-02 | 2020-01-08 | Novartis AG | Protéines hétérodimères modifiées |
SG11201908971RA (en) | 2017-03-31 | 2019-10-30 | Merus Nv | Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene |
US11603407B2 (en) | 2017-04-06 | 2023-03-14 | Regeneron Pharmaceuticals, Inc. | Stable antibody formulation |
TWI788340B (zh) | 2017-04-07 | 2023-01-01 | 美商必治妥美雅史谷比公司 | 抗icos促效劑抗體及其用途 |
CA3065951A1 (fr) | 2017-06-20 | 2018-12-27 | Teneoone, Inc. | Anticorps uniquement a chaines lourdes anti-bcma |
WO2018237037A2 (fr) | 2017-06-20 | 2018-12-27 | Teneobio, Inc. | Anticorps à chaîne lourde uniquement anti-bcma |
GB201710984D0 (en) * | 2017-07-07 | 2017-08-23 | Kymab Ltd | Cells, vertebrates, populations & methods |
TW202348250A (zh) | 2017-07-24 | 2023-12-16 | 美商再生元醫藥公司 | 穩定化之抗體組合物及其製法 |
CN111094351B (zh) | 2017-08-09 | 2024-07-12 | 美勒斯公司 | 结合EGFR和cMET的抗体 |
MX2020002976A (es) | 2017-09-29 | 2020-07-24 | Regeneron Pharma | Moleculas de union a antigeno biespecificas que se unen a un antigeno objetivo de staphylococcus y a un componente de complemento, y usos de las mismas. |
WO2019118556A1 (fr) | 2017-12-13 | 2019-06-20 | Regeneron Pharmaceuticals, Inc. | Associations d'anticorps anti-c5 et utilisations associées |
AU2018392088A1 (en) | 2017-12-22 | 2020-08-13 | Teneobio, Inc. | Heavy chain antibodies binding to CD22 |
CN111886255A (zh) | 2018-01-12 | 2020-11-03 | 百时美施贵宝公司 | 抗tim3抗体及其用途 |
CN111670195B (zh) | 2018-01-26 | 2024-08-13 | 瑞泽恩制药公司 | 针对流感血凝素的人抗体 |
SG11202008767XA (en) | 2018-03-23 | 2020-10-29 | Bristol Myers Squibb Co | Antibodies against mica and/or micb and uses thereof |
SG11202008799PA (en) | 2018-03-24 | 2020-10-29 | Regeneron Pharma | Genetically modified non-human animals for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof |
WO2019212965A1 (fr) | 2018-04-30 | 2019-11-07 | Regeneron Pharmaceuticals, Inc. | Anticorps et molécules de liaison à l'antigène bispécifiques se liant à her2 et/ou aplp2, conjugués et utilisations associées |
MX2020012350A (es) | 2018-05-17 | 2021-01-29 | Regeneron Pharma | Anticuerpos anti-cd63, conjugados y usos de estos. |
IL305557A (en) | 2018-06-14 | 2023-10-01 | Regeneron Pharma | Non-human animals with transgenic DH–DH rearrangement capacity, and their uses |
MX2020013804A (es) | 2018-06-21 | 2021-03-31 | Regeneron Pharma | Anticuerpos anti-psma x anti-cd28 biespecíficos y usos de estos. |
TWI838389B (zh) | 2018-07-19 | 2024-04-11 | 美商再生元醫藥公司 | 雙特異性抗-BCMAx抗-CD3抗體及其用途 |
KR20210049863A (ko) | 2018-08-23 | 2021-05-06 | 리제너론 파아마슈티컬스, 인크. | 항-Fc 엡실론-R1 알파 (FCERIA) 항체, FCERIA 및 CD3에 결합하는 이중특이적 항원-결합 분자 및 이들의 용도 |
WO2020047389A1 (fr) | 2018-08-31 | 2020-03-05 | Regeneron Pharmaceuticals, Inc. | Stratégie de dosage permettant d'atténuer le syndrome de libération de cytokines pour des anticorps bispécifiques cd3/c20 |
JP7439076B2 (ja) | 2018-10-23 | 2024-02-27 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗npr1抗体およびその使用 |
AU2019380307A1 (en) | 2018-11-16 | 2021-07-01 | Bristol-Myers Squibb Company | Anti-NKG2A antibodies and uses thereof |
JP7463366B2 (ja) | 2018-11-20 | 2024-04-08 | タケダ ワクチン,インコーポレイテッド | 新規の抗ジカウイルス抗体及びその使用 |
CN112867732A (zh) | 2018-11-21 | 2021-05-28 | 瑞泽恩制药公司 | 抗葡萄球菌抗体和其用途 |
WO2020132066A1 (fr) | 2018-12-19 | 2020-06-25 | Regeneron Pharmaceuticals, Inc. | Anticorps anti-cd28 x anti-cd22 bispécifiques et leurs utilisations |
AU2019405736A1 (en) | 2018-12-19 | 2021-06-24 | Regeneron Pharmaceuticals, Inc. | Bispecific anti-MUC16 x anti-CD28 antibodies and uses thereof |
WO2020132557A1 (fr) | 2018-12-21 | 2020-06-25 | Compass Therapeutics Llc | Souris transgénique exprimant une chaîne légère humaine commune |
EP3914622A1 (fr) | 2019-01-22 | 2021-12-01 | Bristol-Myers Squibb Company | Anticorps contre la sous-unité alpha d'un l'il-7r et leurs utilisations |
CN117099741A (zh) | 2019-02-18 | 2023-11-24 | 百奥赛图(北京)医药科技股份有限公司 | 具有人源化免疫球蛋白基因座的经遗传修饰的非人动物 |
SG11202107589PA (en) | 2019-02-22 | 2021-08-30 | Regeneron Pharma | Rodents having genetically modified sodium channels and methods of use thereof |
MX2021011500A (es) | 2019-03-22 | 2021-10-22 | Regeneron Pharma | Anticuerpos multiespecificos egfr x cd28. |
BR112021023683A2 (pt) | 2019-06-05 | 2022-02-01 | Regeneron Pharma | Roedor e camundongo geneticamente modificado, embrião de roedor, célula b do roedor ou camundongo geneticamente modificado, hibridoma, população de células b, célula-tronco embrionária, célula de mamífero, métodos de produção de um anticorpo, de uma cadeia pesada, de um domínio variável, de uma coleção de domínios variáveis, de uma cadeia leve, de uma sequência nucleotídica, de um roedor geneticamente modificado e de células es, de geração de um domínio variável e in vitro para gerar uma célula recombinante de roedor, e, vetor de direcionamento |
AU2020292283A1 (en) | 2019-06-11 | 2021-12-23 | Regeneron Pharmaceuticals, Inc. | Anti-PcrV antibodies that bind PcrV, compositions comprising anti-PcrV antibodies, and methods of use thereof |
UY38748A (es) | 2019-06-14 | 2021-01-29 | Teneobio Inc | Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3 |
US20200399372A1 (en) | 2019-06-21 | 2020-12-24 | Regeneron Pharmaceuticals, Inc. | Use of bispecific antigen-binding molecules that bind psma and cd3 in combination with 4-1bb co-stimulation |
AU2020294790A1 (en) | 2019-06-21 | 2021-12-16 | Regeneron Pharmaceuticals, Inc. | Use of bispecific antigen-binding molecules that bind MUC16 and CD3 in combination with 4-1BB co-stimulation |
JP2022543669A (ja) | 2019-08-08 | 2022-10-13 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 新規抗原結合分子フォーマット |
JP2022545647A (ja) | 2019-08-15 | 2022-10-28 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 細胞標的化のための多重特異性抗原結合分子およびそれらの使用 |
GB201912008D0 (en) | 2019-08-21 | 2019-10-02 | Cambridge Entpr Ltd | Antibody |
BR112022007923A2 (pt) | 2019-10-28 | 2022-07-26 | Regeneron Pharma | Anticorpo recombinante isolado ou fragmento de ligação ao antígeno deste, composição farmacêutica, molécula de polinucleotídeo, vetor, célula, e, método para prevenir, tratar ou melhorar pelo menos um sintoma da infecção por influenza |
CA3163549A1 (fr) | 2019-12-02 | 2021-06-10 | Regeneron Pharmaceuticals, Inc. | Constructions proteiques de peptide-cmh ii et leurs utilisations |
AU2020398167A1 (en) | 2019-12-06 | 2022-07-28 | Regeneron Pharmaceuticals, Inc. | Methods of treating multiple myeloma with bispecific anti-BCMA x anti-CD3 antibodies |
KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
US11945872B2 (en) | 2020-02-11 | 2024-04-02 | Regeneron Pharmaceuticals, Inc. | Anti-ACVR1 antibodies and uses thereof |
US20230203161A1 (en) | 2020-04-29 | 2023-06-29 | Teneobio, Inc | Multispecific heavy chain antibodies with modified heavy chain constant regions |
EP4149976A1 (fr) | 2020-05-12 | 2023-03-22 | Regeneron Pharmaceuticals, Inc. | Anticorps antagonistes anti-glp1r et leurs procédés d'utilisation |
US11919956B2 (en) | 2020-05-14 | 2024-03-05 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3 |
US20230192867A1 (en) | 2020-05-15 | 2023-06-22 | Bristol-Myers Squibb Company | Antibodies to garp |
AU2021283564A1 (en) | 2020-06-02 | 2022-12-08 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Genetically modified non-human animals with common light chain immunoglobulin locus |
KR20230166150A (ko) | 2020-08-19 | 2023-12-06 | 젠코어 인코포레이티드 | 항-cd28 조성물 |
IL301137A (en) | 2020-09-11 | 2023-05-01 | Regeneron Pharma | Identification and production of antigen-specific antibodies |
US11905332B2 (en) | 2020-09-18 | 2024-02-20 | Regeneron Pharmaceuticals, Inc. | Antigen-binding molecules that bind CD38 and/or CD28, and uses thereof |
IL301702A (en) | 2020-10-22 | 2023-05-01 | Regeneron Pharma | Anti-FGFR2 antibodies and methods of using them |
CN114524878B (zh) | 2020-11-23 | 2024-08-02 | 康诺亚生物医药科技(成都)有限公司 | 一种双特异性抗体及其用途 |
EP4262373A1 (fr) | 2020-12-16 | 2023-10-25 | Regeneron Pharmaceuticals, Inc. | Souris exprimant des récepteurs humanisés fc alpha |
AU2021410655A1 (en) | 2020-12-23 | 2023-06-29 | Regeneron Pharmaceuticals, Inc. | Nucleic acids encoding anchor modified antibodies and uses thereof |
WO2022140494A1 (fr) | 2020-12-23 | 2022-06-30 | Regeneron Pharmaceuticals, Inc. | Procédés d'obtention d'anticorps qui se lient à des protéines transmembranaires et cellules qui les produisent |
CN116963774A (zh) | 2021-01-28 | 2023-10-27 | 瑞泽恩制药公司 | 用于治疗细胞因子释放综合征的组合物和方法 |
KR20230156079A (ko) | 2021-03-09 | 2023-11-13 | 젠코어 인코포레이티드 | Cd3과 cldn6에 결합하는 이종이량체 항체 |
WO2022192586A1 (fr) | 2021-03-10 | 2022-09-15 | Xencor, Inc. | Anticorps hétérodimères qui se lient au cd3 et au gpc3 |
CA3239802A1 (fr) | 2021-12-06 | 2023-06-15 | Regeneron Pharmaceuticals, Inc. | Anticorps anti-npr1 antagonistes et leurs procedes d'utilisation |
TW202400228A (zh) | 2022-02-25 | 2024-01-01 | 美商再生元醫藥公司 | 減輕細胞激素釋放症候群的給藥方案 |
WO2023196903A1 (fr) | 2022-04-06 | 2023-10-12 | Regeneron Pharmaceuticals, Inc. | Molécules bispécifiques de liaison à l'antigène qui se lient et cd3 et antigènes associés à une tumeur (taa) et leurs utilisations |
WO2023201226A1 (fr) | 2022-04-11 | 2023-10-19 | Regeneron Pharmaceuticals, Inc. | Compositions et méthodes permettant la destruction de cellule tumorale universelle |
US20230416396A1 (en) | 2022-05-18 | 2023-12-28 | Regeneron Pharmaceuticals, Inc. | Multispecific antigen binding molecules that bind cd38 and 4-1bb, and uses thereof |
WO2024015816A1 (fr) | 2022-07-12 | 2024-01-18 | Regeneron Pharmaceuticals, Inc. | Anticorps dirigés contre le récepteur du facteur neurotrophique ciliaire (cntfr) et leurs procédés d'utilisation |
WO2024092133A1 (fr) | 2022-10-27 | 2024-05-02 | Regeneron Pharmaceuticals, Inc. | Anticorps anti-acvr1 et leur utilisation dans le traitement de l'ossification hétérotopique résultant d'un traumatisme |
GB202217978D0 (en) * | 2022-11-30 | 2023-01-11 | Petmedix Ltd | Rodents expressing a common light chain |
WO2024155620A1 (fr) | 2023-01-18 | 2024-07-25 | Gilead Sciences, Inc. | Constructions transgéniques de chaîne légère binaire d'immunoglobuline humaine et leurs utilisations |
WO2024163477A1 (fr) | 2023-01-31 | 2024-08-08 | University Of Rochester | Thérapie de blocage de point de contrôle immunitaire pour le traitement d'infections par staphylococcus aureus |
WO2024173248A1 (fr) | 2023-02-13 | 2024-08-22 | Regeneron Pharmaceuticals, Inc. | Traitement de troubles musculaires avec des anticorps anti-cacng1 humains |
WO2024173830A2 (fr) | 2023-02-17 | 2024-08-22 | Regeneron Pharmaceuticals, Inc. | Cellules nk induites sensibles à des anticorps bispécifiques cd3/taa |
Family Cites Families (140)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990002569A1 (fr) | 1988-09-06 | 1990-03-22 | International Genetic Engineering, Inc. | Production d'anticorps chimeriques murins-humains a specificite pour des antigenes de tumeurs humains |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
WO1991000906A1 (fr) † | 1989-07-12 | 1991-01-24 | Genetics Institute, Inc. | Animaux chimeriques et transgeniques pouvant produire des anticorps humains |
US5574205A (en) | 1989-07-25 | 1996-11-12 | Cell Genesys | Homologous recombination for universal donor cells and chimeric mammalian hosts |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
EP0737746A3 (fr) | 1989-12-01 | 1996-10-23 | Pharming B.V. | Production de polypeptides recombinants par l'espèce bovine et procédés transgéniques |
ATE356869T1 (de) | 1990-01-12 | 2007-04-15 | Amgen Fremont Inc | Bildung von xenogenen antikörpern |
US6657103B1 (en) | 1990-01-12 | 2003-12-02 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6713610B1 (en) | 1990-01-12 | 2004-03-30 | Raju Kucherlapati | Human antibodies derived from immunized xenomice |
US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
WO1994025585A1 (fr) | 1993-04-26 | 1994-11-10 | Genpharm International, Inc. | Animaux transgeniques capables de produire des anticorps heterologues |
US7084260B1 (en) | 1996-10-10 | 2006-08-01 | Genpharm International, Inc. | High affinity human antibodies and human antibodies against human antigens |
ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
US7041871B1 (en) | 1995-10-10 | 2006-05-09 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5667988A (en) | 1992-01-27 | 1997-09-16 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
US7067284B1 (en) | 1992-01-27 | 2006-06-27 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
ATE381614T1 (de) | 1992-07-24 | 2008-01-15 | Amgen Fremont Inc | Bildung von xenogenen antikörpern |
DE69308573T2 (de) | 1992-08-17 | 1997-08-07 | Genentech Inc | Bispezifische immunoadhesine |
US5693506A (en) | 1993-11-16 | 1997-12-02 | The Regents Of The University Of California | Process for protein production in plants |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
ATE213771T1 (de) | 1993-12-23 | 2002-03-15 | Infigen Inc | Embryonale stammzellen von huftieren als kerndonatoren und kerntransfertechniken zur herstellung chimärer und transgener tiere |
EP0744958B1 (fr) | 1994-01-31 | 2003-06-25 | Trustees Of Boston University | Banques d'anticorps polyclonaux |
US7119248B1 (en) | 1994-04-12 | 2006-10-10 | Miltenyi Biotec Gmbh | Antibodies against epitopes with homology to self antigens, methods of preparation and applications thereof |
US6080560A (en) | 1994-07-25 | 2000-06-27 | Monsanto Company | Method for producing antibodies in plant cells |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
EP0826696B1 (fr) | 1996-09-03 | 2002-05-29 | GSF-Forschungszentrum für Umwelt und Gesundheit GmbH | Utilisation des anticorps bi- et trispécifiques pour induire une immunité antitumorale |
EP2305027B1 (fr) | 1996-12-03 | 2014-07-02 | Amgen Fremont Inc. | Mammifères trangèniques obtenus par génie génétique contenant des loci des immunoglobulines humaines qui comprennent plusieurs régions de VH et de Vkappa, et anticorps aussi obtenus. |
EP0973871A1 (fr) | 1997-03-06 | 2000-01-26 | Infigen, Inc. | Methode de clonage d'animaux |
US7227002B1 (en) | 1997-04-14 | 2007-06-05 | Micromet Ag | Human antibodies that bind human 17-A1/EpCAM tumor antigen |
US20020062010A1 (en) * | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
CA2288600C (fr) | 1997-05-02 | 2010-06-01 | Genentech, Inc. | Procede de preparation d'anticorps multispecifiques presentant des composants heteromultimeres |
US6774279B2 (en) | 1997-05-30 | 2004-08-10 | Carnegie Institution Of Washington | Use of FLP recombinase in mice |
RU2221809C2 (ru) | 1997-10-03 | 2004-01-20 | Тугаи Сейяку Кабусики Кайся | Способ получения природного гуманизированного антитела |
DK1034262T3 (da) | 1997-11-18 | 2005-11-28 | Pioneer Hi Bred Int | Sammensætninger og fremgangsmåder til genetisk modifikation af planter |
GB9823930D0 (en) | 1998-11-03 | 1998-12-30 | Babraham Inst | Murine expression of human ig\ locus |
US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
ES2335775T3 (es) | 1999-04-15 | 2010-04-05 | Crucell Holland B.V. | Produccion de protenia recombinante en una celula humana que comprende al menos una proteina e1 de adenovirus. |
CA2401965A1 (fr) | 2000-02-29 | 2001-09-07 | Auburn University | Production d'anticorps dans des plastes transgeniques |
CN101498731A (zh) | 2000-05-18 | 2009-08-05 | 日本烟草产业株式会社 | 抗协同刺激信号转导分子ailim的人单克隆抗体及其药物用途 |
WO2002008409A2 (fr) | 2000-07-21 | 2002-01-31 | The United States Of America, As Represented By The Secretary Of Agriculture | Procedes de remplacement, transposition et empilage de l'adn dans des genomes eucaryotes |
WO2002012437A2 (fr) | 2000-08-03 | 2002-02-14 | Schooten Wim Van | Production d'anticorps humanises dans des animaux transgeniques |
EP1184458A1 (fr) | 2000-08-28 | 2002-03-06 | U-BISys B.V. | Epitopes de CD46 exprimés différentiellement, des molécules protéiniques capables de s'y lier, et leurs utilisations |
US20020119148A1 (en) | 2000-09-01 | 2002-08-29 | Gerritsen Mary E. | ErbB4 antagonists |
US7105348B2 (en) | 2000-10-31 | 2006-09-12 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
PL217921B1 (pl) | 2001-01-05 | 2014-09-30 | Amgen Fremont Inc | Przeciwciało przeciw receptorowi insulinopodobnego czynnika wzrostu I, zawierająca go kompozycja farmaceutyczna, sposób jego wytwarzania, zastosowania, linia komórkowa, wyizolowana cząsteczka kwasu nukleinowego, wektor, komórka gospodarza oraz zwierzę transgeniczne |
US6961875B2 (en) | 2001-03-22 | 2005-11-01 | International Business Machines Corporation | Method and apparatus for capturing event traces for debug and analysis |
GB0110029D0 (en) | 2001-04-24 | 2001-06-13 | Grosveld Frank | Transgenic animal |
JP4303105B2 (ja) | 2001-06-28 | 2009-07-29 | ドマンティス リミテッド | 二重特異性リガンドとその利用 |
AU2002368077B2 (en) | 2001-07-12 | 2010-03-04 | Jefferson Foote | Super humanized antibodies |
WO2003062370A2 (fr) | 2001-07-19 | 2003-07-31 | Perlan Therapeutics, Inc. | Proteines multimeres et methodes de production et d'utilisation de ces proteines |
ES2350248T3 (es) | 2001-10-01 | 2011-01-20 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Procedimiento de producción de bibliotecas de proteínas y de selección de proteínas a partir de las mismas. |
WO2003031656A1 (fr) | 2001-10-05 | 2003-04-17 | United States Environmental Protection Agency | Evaluation genetique du facteur de sterilite masculine |
US20060199204A1 (en) | 2001-10-05 | 2006-09-07 | U.S. Epa | Genetic testing for male factor infertility |
CA2847885C (fr) | 2001-11-30 | 2022-03-22 | Amgen Fremont Inc. | Animaux transgeniques porteurs de genes a chaine legere iglamba d'immunoglobuline humaine |
GB0130267D0 (en) | 2001-12-19 | 2002-02-06 | Neutec Pharma Plc | Focussed antibody technology |
US20050095712A1 (en) | 2002-01-17 | 2005-05-05 | Alberto Martin | Mutations caused by activation-induced cytidine deaminase |
EP1470161A1 (fr) | 2002-01-18 | 2004-10-27 | Inovio AS | Constructions d'adn d'anticorps bispecifique pour administration intramusculaire muscle |
JP4518941B2 (ja) | 2002-04-26 | 2010-08-04 | 中外製薬株式会社 | アゴニスト抗体のスクリーニング方法 |
CN1675245B (zh) | 2002-06-14 | 2011-01-12 | 免疫医疗公司 | 人源化单克隆抗体hPAM4 |
CN101962408A (zh) | 2002-07-12 | 2011-02-02 | 杰斐逊·富特 | 超人源化抗体 |
ES2368733T3 (es) * | 2002-07-18 | 2011-11-21 | Merus B.V. | Producción recombinante de mezclas de anticuerpos. |
CL2003002461A1 (es) | 2002-11-27 | 2005-01-07 | Dow Chemical Company Agroscien | Inmunoglobulina que comprende al menos un glicano afucosilado, composicion que la contiene, secuencia nucleotidica y vector que la comprende, procedimiento para producir dicha inmunoglobulina en plantas. |
GB0228210D0 (en) | 2002-12-03 | 2003-01-08 | Babraham Inst | Single chain antibodies |
GB0230203D0 (en) | 2002-12-27 | 2003-02-05 | Domantis Ltd | Fc fusion |
EP1439234A1 (fr) | 2003-01-08 | 2004-07-21 | ARTEMIS Pharmaceuticals GmbH | Transgénèse ciblée utilisant le locus 26 |
ATE431423T1 (de) | 2003-01-21 | 2009-05-15 | Chugai Pharmaceutical Co Ltd | Verfahren zum screening der leichten kette eines antikörpers |
AU2004208031B2 (en) | 2003-01-28 | 2009-10-08 | Cellectis | Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof. |
CA2517519A1 (fr) | 2003-03-04 | 2004-09-16 | Alexion Pharmaceuticals, Inc. | Vecteurs utilises pour creer des regions hybrides constantes |
EP2395016A3 (fr) | 2003-05-30 | 2012-12-19 | Merus B.V. | Conception et utilisation de régions variables appariées de molécules de liaison spécifiques |
US20100069614A1 (en) | 2008-06-27 | 2010-03-18 | Merus B.V. | Antibody producing non-human mammals |
US7585668B2 (en) | 2003-07-15 | 2009-09-08 | Therapeutic Human Polyclonals, Inc. | Humanized immunoglobulin loci |
WO2005019463A1 (fr) | 2003-08-11 | 2005-03-03 | Therapeutic Human Polyclonals, Inc. | Amelioration de la transgenese a l'aide de loci d'immunoglobuline humanises |
WO2005038001A2 (fr) | 2003-10-14 | 2005-04-28 | Therapeutic Human Polyclonals, Inc. | Transgenese amelioree par transfert genique a mediation spermatique |
DK1709081T3 (da) | 2004-01-16 | 2011-06-06 | Regeneron Pharma | Fusionspolypeptider, der kan aktivere receptorer |
CN1560081A (zh) | 2004-02-17 | 2005-01-05 | 大连帝恩生物工程有限公司 | 用能产生人IgGl重链-κ轻链小鼠作为制备人源化单克隆抗体和应用 |
US7625549B2 (en) | 2004-03-19 | 2009-12-01 | Amgen Fremont Inc. | Determining the risk of human anti-human antibodies in transgenic mice |
DK1802193T3 (da) | 2004-10-19 | 2014-06-10 | Regeneron Pharma | Fremgangsmåde til frembringelse af en homozygot mus til genetisk modifikation |
CN101084317A (zh) | 2004-10-22 | 2007-12-05 | 人类多克隆治疗公司 | 对内源免疫球蛋白表达的抑制 |
CN102731654A (zh) * | 2004-10-22 | 2012-10-17 | 米迪缪尼有限公司 | 抗hmgb1的高亲和力抗体及其用法 |
WO2006117699A2 (fr) | 2005-04-29 | 2006-11-09 | Innate Pharma | Animaux transgeniques et procedes de fabrication d'anticorps recombines |
US20100154070A1 (en) | 2005-05-14 | 2010-06-17 | Tian Xu | PiggyBac as a Tool for Genetic Manipulation and Analysis in Vertebrates |
FR2888850B1 (fr) | 2005-07-22 | 2013-01-11 | Pf Medicament | Nouveaux anticorps anti-igf-ir et leurs applications |
AU2006322445B2 (en) * | 2005-12-05 | 2011-05-12 | Symphogen A/S | Anti-orthopoxvirus recombinant polyclonal antibody |
SG169348A1 (en) | 2006-01-25 | 2011-03-30 | Univ Erasmus Medical Ct | Generation of heavy-chain only antibodies in transgenic animals |
US7462759B2 (en) | 2006-02-03 | 2008-12-09 | Pioneer Hi-Bred International, Inc. | Brittle stalk 2 gene family and related methods and uses |
US7910798B2 (en) | 2006-03-31 | 2011-03-22 | Medarex, Inc. | Transgenic animals expressing chimeric antibodies for use in preparing human antibodies |
CN102585002A (zh) | 2006-06-02 | 2012-07-18 | 瑞泽恩制药公司 | 人il-6受体的高亲和力抗体 |
CN101501073A (zh) | 2006-08-22 | 2009-08-05 | G2英弗勒美欣私人有限公司 | 抗体制备方法 |
US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
EP2069403B1 (fr) | 2006-10-02 | 2014-05-07 | Regeneron Pharmaceuticals, Inc. | Anticorps humains à haute affinité vis-à-vis du récepteur il-4 humain |
RU2448979C2 (ru) | 2006-12-14 | 2012-04-27 | Ридженерон Фармасьютикалз, Инк. | Антитела человека к дельта-подобному лиганду-4 человека |
GB0700194D0 (en) | 2007-01-05 | 2007-02-14 | Univ Edinburgh | Humanisation of animals |
CN101688228B (zh) | 2007-03-13 | 2014-12-24 | 国家犾太健康中心 | 抗体产生的方法 |
CN101784664B (zh) | 2007-06-01 | 2013-04-10 | Omt公司 | 用于抑制内源性免疫球蛋白基因和生产转基因人独特型抗体的组合物和方法 |
WO2009013620A2 (fr) | 2007-06-11 | 2009-01-29 | Erasmus University Medical Center Rotterdam | Recombinaison homologue |
ITMI20071522A1 (it) * | 2007-07-27 | 2009-01-28 | Areta Internat S R L | Vaccino idiotipico |
EP3255144A1 (fr) | 2007-08-10 | 2017-12-13 | E. R. Squibb & Sons, L.L.C. | Construction de type recombineering pour la préparation de souris transgeniques capables de produire des immunoglobulines humaines. |
CA2695374A1 (fr) | 2007-08-15 | 2009-02-19 | Amunix, Inc. | Compositions et procedes d'amelioration de la production de polypeptides recombines |
US8691730B2 (en) | 2007-09-14 | 2014-04-08 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
EP2211903A4 (fr) | 2007-10-17 | 2011-07-06 | Nuvelo Inc | Anticorps anti-cll-1 |
BRPI0821658B8 (pt) | 2007-12-14 | 2021-05-25 | Novo Nordisk As | anticorpo monoclonal humano ou um fragmento de ligação ao antígeno do mesmo que se liga a hnkg2d e seus usos |
MX350962B (es) | 2008-01-07 | 2017-09-27 | Amgen Inc | Metodo para fabricar moleculas heterodimericas de fragmentos cristalizables de anticuerpo, utilizando efectos electrostaticos de direccion. |
CA2721231C (fr) | 2008-04-14 | 2015-10-06 | Innovative Targeting Solutions Inc. | Creation de diversite de sequences dans des immunoglobulines |
AU2009248834B2 (en) | 2008-05-23 | 2014-10-30 | Ablexis Llc | Method of generating single VL domain antibodies in transgenic animals |
EP3456193A1 (fr) | 2008-06-27 | 2019-03-20 | Merus N.V. | Mammifères non humains produisant un anticorps |
LT2346994T (lt) | 2008-09-30 | 2022-03-10 | Ablexis, Llc | Knock-in pelė, skirta chimerinių antikūnų gamybai |
JP5882058B2 (ja) | 2008-11-07 | 2016-03-09 | ファブラス エルエルシー | 組合せ抗体ライブラリー及びその使用 |
WO2010070263A1 (fr) | 2008-12-18 | 2010-06-24 | Erasmus University Medical Center Rotterdam | Animaux transgeniques non humains exprimant des anticorps humanises et leur utilisation |
EP2401298A1 (fr) | 2009-02-24 | 2012-01-04 | Glaxo Group Limited | Constructions de liaison d'antigène |
US8808136B2 (en) | 2009-05-07 | 2014-08-19 | Volvo Construction Equipment Ab | Working machine and a method for operating a working machine |
CA2758356C (fr) | 2009-05-29 | 2016-07-26 | Morphosys Ag | Une collection de paires de vh et de vl ayant des proprietes biophysiques favorables et ses methodes d'utilisation |
EP3916011A1 (fr) | 2009-06-26 | 2021-12-01 | Regeneron Pharmaceuticals, Inc. | Anticorps bispécifiques facilement isolés avec un format natif d'immunoglobuline |
ES2537239T3 (es) | 2009-07-08 | 2015-06-03 | Kymab Limited | Modelos de animales y moléculas terapéuticas |
US9315824B2 (en) | 2009-11-17 | 2016-04-19 | Sab, Llc | Human artificial chromosome vector |
JP5909449B2 (ja) | 2009-12-10 | 2016-04-26 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | 重鎖抗体を作製するマウス |
US20130045492A1 (en) | 2010-02-08 | 2013-02-21 | Regeneron Pharmaceuticals, Inc. | Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain |
US9796788B2 (en) | 2010-02-08 | 2017-10-24 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
US20120021409A1 (en) | 2010-02-08 | 2012-01-26 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
BR122014002928A2 (pt) | 2010-02-08 | 2015-12-29 | Regeneron Pharma | métodos de produzir um camundongo e um anticorpo e de selecionar uma região variável de cadeia pesada humana para a produção de uma proteína de ligação ao antígeno, uso de um camundongo geneticamente modificado na produção de uma proteína de ligação ao antígeno, bem como anticorpo quimérico e hibridoma |
US20130185821A1 (en) | 2010-02-08 | 2013-07-18 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
EP2569337A1 (fr) | 2010-05-14 | 2013-03-20 | Rinat Neuroscience Corp. | Protéines hétérodimériques et leurs procédés de production et de purification |
NZ605966A (en) | 2010-06-17 | 2015-04-24 | Kymab Ltd | Animal models and therapeutic molecules |
BR122020013427B1 (pt) | 2010-06-22 | 2021-08-03 | Regeneron Pharmaceuticals, Inc | Método para fazer um camundongo, uma célula ou tecido derivado de um camundongo e um hibridoma |
MX363084B (es) | 2010-08-02 | 2019-03-07 | Regeneron Pharma | Ratones que producen proteinas de union que comprenden dominios vl. |
CN103429746B (zh) | 2011-02-25 | 2016-05-11 | 瑞泽恩制药公司 | Adam6小鼠 |
SG2014007686A (en) | 2011-08-05 | 2014-03-28 | Regeneron Pharma | Humanized universal light chain mice |
CA2791109C (fr) | 2011-09-26 | 2021-02-16 | Merus B.V. | Generation de molecules de liaison |
EP4074833A1 (fr) | 2011-10-17 | 2022-10-19 | Regeneron Pharmaceuticals, Inc. | Souris à chaîne lourde d'immunoglobuline limitée |
GB201122047D0 (en) | 2011-12-21 | 2012-02-01 | Kymab Ltd | Transgenic animals |
SG11201405088QA (en) | 2012-03-06 | 2014-11-27 | Regeneron Pharma | Common light chain mouse |
WO2013157953A1 (fr) | 2012-04-20 | 2013-10-24 | Merus B.V. | Procédés et moyens de production de molécules de type ig |
JP2015525071A (ja) | 2012-06-05 | 2015-09-03 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | 共通の軽鎖を用いて完全ヒト型二重特異性抗体を作製するための方法 |
BR112015022034B1 (pt) | 2013-03-13 | 2023-02-28 | Regeneron Pharmaceuticals, Inc | Método de fabricar um camundongo, e, para fabricar um anticorpo |
CN105189545A (zh) | 2013-03-13 | 2015-12-23 | 瑞泽恩制药公司 | 常见轻链小鼠 |
-
2011
- 2011-02-08 BR BR122014002928A patent/BR122014002928A2/pt not_active Application Discontinuation
- 2011-02-08 NZ NZ631363A patent/NZ631363A/en unknown
- 2011-02-08 KR KR1020127021534A patent/KR101829691B1/ko active IP Right Grant
- 2011-02-08 SI SI201131725T patent/SI3095871T1/sl unknown
- 2011-02-08 HU HUE11703799A patent/HUE026229T2/en unknown
- 2011-02-08 SG SG2012057485A patent/SG183149A1/en unknown
- 2011-02-08 ES ES16178223T patent/ES2728942T3/es active Active
- 2011-02-08 ES ES11703799T patent/ES2547142T5/es active Active
- 2011-02-08 RS RS20161014A patent/RS55315B2/sr unknown
- 2011-02-08 DK DK16178223.0T patent/DK3095871T3/da active
- 2011-02-08 PL PL12173456T patent/PL2505654T5/pl unknown
- 2011-02-08 PL PL11703799T patent/PL2501817T5/pl unknown
- 2011-02-08 SG SG10201500821UA patent/SG10201500821UA/en unknown
- 2011-02-08 SI SI201131024T patent/SI2505654T2/sl unknown
- 2011-02-08 DK DK11703799.4T patent/DK2501817T4/da active
- 2011-02-08 PT PT121734560T patent/PT2505654T/pt unknown
- 2011-02-08 AU AU2011213585A patent/AU2011213585B2/en active Active
- 2011-02-08 TR TR2019/06650T patent/TR201906650T4/tr unknown
- 2011-02-08 PL PL16178223T patent/PL3095871T3/pl unknown
- 2011-02-08 MY MYPI2012003497A patent/MY166529A/en unknown
- 2011-02-08 EP EP19157278.3A patent/EP3540066A1/fr active Pending
- 2011-02-08 US US13/022,759 patent/US10143186B2/en active Active
- 2011-02-08 JP JP2012552144A patent/JP5955781B2/ja active Active
- 2011-02-08 NZ NZ719253A patent/NZ719253A/en unknown
- 2011-02-08 KR KR1020197018579A patent/KR102116296B1/ko active IP Right Grant
- 2011-02-08 RU RU2015147726A patent/RU2724663C2/ru active
- 2011-02-08 PT PT117037994T patent/PT2501817E/pt unknown
- 2011-02-08 RS RS20150772A patent/RS54367B2/sr unknown
- 2011-02-08 KR KR1020187003853A patent/KR101995735B1/ko active IP Right Grant
- 2011-02-08 MX MX2015007651A patent/MX350983B/es unknown
- 2011-02-08 ES ES12173456T patent/ES2603559T5/es active Active
- 2011-02-08 RU RU2012138431/10A patent/RU2571205C2/ru active
- 2011-02-08 ME MEP-2016-271A patent/ME02646B/fr unknown
- 2011-02-08 HU HUE12173456A patent/HUE029785T2/en unknown
- 2011-02-08 CA CA2789154A patent/CA2789154C/fr active Active
- 2011-02-08 KR KR1020217023446A patent/KR102432611B1/ko active IP Right Grant
- 2011-02-08 CN CN201510354745.2A patent/CN105010238B/zh active Active
- 2011-02-08 PT PT16178223T patent/PT3095871T/pt unknown
- 2011-02-08 WO PCT/US2011/023971 patent/WO2011097603A1/fr active Application Filing
- 2011-02-08 SG SG10201913463QA patent/SG10201913463QA/en unknown
- 2011-02-08 CN CN201180013714.0A patent/CN102791866B/zh active Active
- 2011-02-08 HU HUE16178223A patent/HUE045591T2/hu unknown
- 2011-02-08 RS RS20190849A patent/RS59001B1/sr unknown
- 2011-02-08 EP EP12173456.0A patent/EP2505654B2/fr active Active
- 2011-02-08 LT LTEP16178223.0T patent/LT3095871T/lt unknown
- 2011-02-08 EP EP16178223.0A patent/EP3095871B1/fr active Active
- 2011-02-08 SI SI201130642T patent/SI2501817T2/sl unknown
- 2011-02-08 ME MEP-2015-197A patent/ME02288B/me unknown
- 2011-02-08 LT LTEP12173456.0T patent/LT2505654T/lt unknown
- 2011-02-08 NZ NZ601679A patent/NZ601679A/en unknown
- 2011-02-08 DK DK12173456.0T patent/DK2505654T4/da active
- 2011-02-08 KR KR1020207014664A patent/KR102283195B1/ko active IP Right Grant
- 2011-02-08 EP EP11703799.4A patent/EP2501817B2/fr active Active
- 2011-02-08 BR BR112012019887-4A patent/BR112012019887B1/pt active IP Right Grant
- 2011-02-08 NZ NZ619512A patent/NZ619512A/en unknown
- 2011-02-08 MX MX2012009168A patent/MX2012009168A/es active IP Right Grant
-
2012
- 2012-03-06 US US13/412,936 patent/US20120192300A1/en not_active Abandoned
- 2012-08-02 IL IL221265A patent/IL221265B/en active IP Right Grant
- 2012-08-07 ZA ZA2012/05944A patent/ZA201205944B/en unknown
- 2012-08-08 MX MX2021000286A patent/MX2021000286A/es unknown
- 2012-10-17 HK HK17104973.4A patent/HK1231505A1/zh unknown
-
2013
- 2013-02-06 HK HK13101647.0A patent/HK1174358A1/zh unknown
- 2013-03-05 SG SG10201610294RA patent/SG10201610294RA/en unknown
- 2013-07-23 US US13/948,818 patent/US20130302836A1/en not_active Abandoned
-
2015
- 2015-07-02 JP JP2015133610A patent/JP6215264B2/ja active Active
- 2015-11-05 HR HRP20151188TT patent/HRP20151188T4/hr unknown
- 2015-11-19 SM SM201500283T patent/SMT201500283B/it unknown
-
2016
- 2016-11-17 CY CY20161101191T patent/CY1118241T1/el unknown
- 2016-11-22 HR HRP20161551TT patent/HRP20161551T4/hr unknown
- 2016-11-24 SM SM201600432T patent/SMT201600432B/it unknown
-
2017
- 2017-05-24 JP JP2017102567A patent/JP6470789B2/ja active Active
-
2018
- 2018-05-01 JP JP2018088350A patent/JP2018138047A/ja active Pending
- 2018-10-19 US US16/165,987 patent/US10986820B2/en active Active
-
2019
- 2019-01-18 JP JP2019006594A patent/JP6666483B2/ja active Active
- 2019-06-16 IL IL267362A patent/IL267362B/en unknown
- 2019-07-01 HR HRP20191191TT patent/HRP20191191T1/hr unknown
- 2019-07-05 CY CY20191100710T patent/CY1121794T1/el unknown
-
2020
- 2020-02-20 JP JP2020027029A patent/JP6960005B2/ja active Active
-
2021
- 2021-03-23 US US17/209,964 patent/US20210204531A1/en active Pending
- 2021-10-08 JP JP2021166030A patent/JP7233504B2/ja active Active
-
2022
- 2022-01-24 IL IL290085A patent/IL290085A/en unknown
-
2023
- 2023-02-21 JP JP2023025117A patent/JP7538907B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL290085A (en) | A common light chain mouse | |
AU2016202488A1 (en) | Common light chain mouse | |
HK1205873A1 (en) | Common light chain mouse | |
ZA201404600B (en) | Hybrid light chain mice | |
EP2609366A4 (fr) | Accessoire lumineux | |
AU2014202445B2 (en) | Common light chain mouse | |
GB2478365B (en) | Light | |
TWM389815U (en) | LED light | |
TWM387201U (en) | Light | |
AU330289S (en) | Light | |
AU329890S (en) | Light | |
GB201014527D0 (en) | Chain | |
AU334604S (en) | Luminaire | |
AU334605S (en) | Luminaire | |
GB201017396D0 (en) | Luminaire |